Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Current Therapeutic Research - Clinical and Experimental

Volumn 71, Issue 4, 2010, Pages 211-238

  Li, Wei Xin ^a   Gou, Jian Feng ^a   Tian, Jin Hui ^a   Yan, Xiang ^a   Yang, Lin ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Diabetes mellitus; GLP 1; Glucagon like peptide 1; Insulin detemir; Insulin glargine; Meta analysis; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INSULIN GLARGINE; LIPID; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA;

ARTHRALGIA; BACKACHE; BEDTIME DOSAGE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DYSPEPSIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INFLUENZA; META ANALYSIS; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN;

EID: 77958617703     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2010.08.003     Document Type: Review

References (46)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27:1047-1053.
2. Kahn SE The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003, 46:3-19.
3. Scheen AJ Antidiabetic agents in subjects with mild dysglycaemia: Prevention or early treatment of type 2 diabetes?. Diabetes Metab. 2007, 33:3-12.
4. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appeats in Diabetes. 1996;45:1655]. Diabetes. 1995, 44:1249-1258. UK Prospective Diabetes Study Group, UK Prospective Diabetes Study 16UK Prospective Diabetes Study 16.
5. Tutner RC, Cull CA, Frighi V, Holman RR Glycemic control with diet, sulfonylurea, metfotmin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999, 281:2005-2012. UK Prospective Diabetes Study (UKPDS) Group.
6. Levetan C Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007, 23:945-952.
7. Hansen KB, Knop FK, Holst JJ, Vilsbøll T Treatment of type 2 diabetes with glucagon-like peptide-1 receptot agonists. Int J Clin Pract. 2009, 63:1154-1160.
8. Goykhman S, Drincic A, Desmangles JC, Rendell M Insulin glargine: A review 8 years after its introduction. Expert Opin Pharmacother. 2009, 10:705-718.
9. Goldman-Levine JD, Lee KW Insulin detemir-a new basal insulin analog. Ann Pharmacother. 2005, 39:502-507.
10. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregu-latory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002, 87:1239-1246.
11. Vilsbøll T, Krarup T, Madsbad S, Holst JJ Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003, 114:115-121.
12. Flint A, Raben A, Astrup A, Holst JJ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998, 101:515-520.
13. Zander M, Madsbad S, Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet. 2002, 359:824-830.
14. Baggio LL, Drucker DJ Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132:2131-2157.
15. Gallwitz B Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data. Int J Clin Pract. 2006, 60:1654-1661.
16. Nielsen LL, Young AA, Parkes DG Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004, 117:77-88.
17. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000, 43:1664-1669.
18. Wajcberg E, Tavaria A Exenatide: Clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2009, 10:135-142.
19. Neumiller JJ, Campbell RK Liraglutide: A once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009, 43:1433-1444.
20. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagonlike peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008, 93:4810-4817. Albiglutide Study Group.
21. Christensen M, Knop FK, Holst JJ, Vilsboll T Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009, 12:503-513.
22. Rettetstøl K Taspoglutide: A long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs. 2009, 18:1405-1411.
23. Alberti KG, Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15:539-553.
24. Standards of medical care in diabetes-2009. Diabetes Care. 2009, 32(Suppl 1):S13-S61. American Diabetes Association.
25. Cochrane Handbook for Systematic Reviews of Interventions 2009, The Cochrane Collaboration, Version 5.0.2 [updated September 2009], Accessed June 22, 2010. http://www.cochrane-handbook.org, J.P. Higgins, S. Green (Eds.).
26. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2005, 143:559-569. GWAA Study Group.
27. Barnett AH, Butget J, Johns D, et al. Tolerability and efficacy of exenatide and tittated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007, 29:2333-2348.
28. Bunck MC, Diamant M, Cotnér A, et al. One-year treatment with exenatide improves beta-cell function, compated with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care. 2009, 32:762-768.
29. Russell-Jones D, Vaag A, Schmitz O Liraglutide vs insulin glatgine and placebo in combination with metfotmin and sulfonylurea thetapy in type 2 diabetes mellitus (LEAD-5 met+SU): A tandomised conrrolled trial. Diabetologia. 2009, 52:2046-2055. Litaglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.
30. Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compated with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the Helping Evaluate Exenatide in patients with diabetes compated with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009, 11:1153-1162.
31. Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes. 2006, 4:80.
32. Mittendorf T, Smith-Palmer J, Timlin L, et al. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: Cost-effectiveness analysis in the Getman setting. Diabetes Obes Metab. 2009, 11:1068-1079.
33. Brändie M, Erny-Albrecht KM, Goodall G, et al. Exenatide versus insulin glargine: A cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2009, 47:501-515.
34. Woehl A, Evans M, Tetlow AP, McEwan P Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol. 2008, 7:24.
35. Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: A model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007, 23:609-622.
36. Amoti RE, Lau J, Pittas AG Efficacy and safety of inctetin thetapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007, 298:194-206.
37. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000, 321:405-412.
38. Cai J, Pajak A, Li Y, et al. Total cholesterol and mottality in China, Poland, Russia, and the US. Ann Epidemiol. 2004, 14:399-408.
39. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vasculat mottality: A meta-analysis of individual data fot one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361:1060]. Lancet. 2002, 360:1903-1913. Prospective Studies Collaborarion.
40. Williams B The Hypertension in Diabetes Study (HDS): A catalyst for change. Diabet Med. 2008, 25(Suppl 2):13-19.
41. I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993, 11:309-317. Hyperrension in Diabetes Study (HDS).
42. II. Incteased risk of catdiovasculat complications in hypettensive type 2 diabetic patients [published correction appeals in J Hypertens. 1993;11:681]. J Hypertens. 1993, 11:319-325. Hypertension in Diabetes Study (HDS).
43. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as detetminants of cardiovascular risk: The Framingham experience. Arch Intern Med. 2002, 162:1867-1872.
44. Whitmote C Type 2 diabetes and obesity in adults. Br J Nurs. 2010, 19:880-886.
45. Yusuf HR, Giles WH, Croft JB, et al. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med. 1998, 27:1-9.
46. Gerich JE Postprandial hyperglycemia and cardiovascular disease. Endocr Pract. 2006, 12(Suppl 1):47-51.